GLP-1: Research & Studies

Research Overview#

GLP-1 research spans from the fundamental discovery of the incretin effect in the 1960s through the development and clinical validation of one of the most important drug classes in modern medicine. The evidence base for GLP-1 receptor agonists is exceptionally deep, with multiple large-scale randomized controlled trials demonstrating efficacy in diabetes, obesity, and cardiovascular disease.

Discovery and Early Research#

The Incretin Effect#

The observation that oral glucose produces a greater insulin response than intravenous glucose at equivalent blood glucose levels was first described by Elrick and colleagues in 1964 and further characterized by Creutzfeldt and others. This "incretin effect" was attributed to gut-derived hormones released during meal absorption. GIP was identified first, but GLP-1 was subsequently recognized as the more potent incretin hormone.

GLP-1 Characterization#

The cloning of the proglucagon gene by Habener, Drucker, and others in the 1980s revealed that the glucagon precursor also encoded GLP-1 and GLP-2. Holst and colleagues in Copenhagen demonstrated that GLP-1(7-36)amide was a potent insulinotropic hormone with glucose-dependent activity — a property that immediately suggested therapeutic potential because it implied a built-in safety mechanism against hypoglycemia.

Satiety Research#

The 1998 study by Flint and colleagues was a milestone in establishing GLP-1's role in appetite regulation. Intravenous infusion of GLP-1 in healthy subjects reduced food intake by 12% and increased ratings of satiety and fullness. This finding provided the scientific foundation for the development of GLP-1 receptor agonists as obesity treatments — an application that would take over two decades to reach its full clinical impact.

Landmark Clinical Trials#

LEADER Trial (Liraglutide)#

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, published in 2016, was a watershed moment for the GLP-1 RA class. This trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg daily versus placebo over a median follow-up of 3.8 years.

The primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (MACE) was significantly reduced by 13% with liraglutide. Cardiovascular death was reduced by 22%, and all-cause mortality was reduced by 15%. These results established liraglutide as the first GLP-1 RA with demonstrated cardiovascular benefit, fundamentally changing diabetes treatment guidelines.

SUSTAIN-6 Trial (Semaglutide)#

The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) showed a 26% reduction in MACE with injectable semaglutide 0.5 mg and 1.0 mg weekly versus placebo, driven primarily by a reduction in non-fatal stroke. This confirmed the cardiovascular benefits of the GLP-1 RA class with an even more potent agent.

STEP Trials (Semaglutide for Obesity)#

The Semaglutide Treatment Effect in People with Obesity (STEP) program comprised multiple Phase 3 trials evaluating semaglutide 2.4 mg weekly for weight management:

• STEP 1: 14.9% mean weight loss in adults with obesity (vs 2.4% placebo)
• STEP 2: 9.6% weight loss in adults with T2D and obesity
• STEP 3: 16.0% weight loss when combined with intensive behavioral therapy
• STEP 4: Continued treatment maintained weight loss; withdrawal led to weight regain

These results established semaglutide as the most effective pharmacological weight loss agent approved to date (at the time), producing weight loss approaching that of bariatric surgery in some patients.

SURMOUNT Trials (Tirzepatide)#

The tirzepatide SURMOUNT-1 trial demonstrated even greater weight loss than semaglutide, with mean reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks. These unprecedented results with a dual GIP/GLP-1 agonist suggested that combining incretin pathways produces additive or synergistic metabolic benefits.

Emerging Research Areas#

Cardiovascular Protection#

Beyond diabetes, the SELECT trial (semaglutide in obese/overweight patients without diabetes) demonstrated cardiovascular benefit independent of glucose lowering, expanding the potential population for GLP-1 RA therapy.

Liver Disease#

GLP-1 RAs are being studied for nonalcoholic steatohepatitis (NASH/MASH), with semaglutide showing histological improvement in liver fibrosis and inflammation in Phase 2 trials.

Neurodegeneration#

Observational data and early clinical trials suggest potential neuroprotective effects of GLP-1 RAs in Alzheimer's disease and Parkinson's disease, based on GLP-1 receptor expression in the brain and preclinical evidence of anti-inflammatory and neurotrophic effects.

Evidence Quality Assessment#

The evidence base for GLP-1 receptor agonists is rated as high, supported by multiple large-scale randomized controlled trials with tens of thousands of participants, long-term follow-up data, and robust mechanistic understanding. The evidence for native GLP-1 biology is also exceptionally strong, with decades of consistent research across species.

Related Reading#

• GLP-1 overview and research guide
• GLP-1 dosing protocols
• GLP-1 molecular structure